Skip to content

Clinical Outcome and Cytokine Expression After TKA

Clinical Outcome and Cytokine Expression in Blood After Coated in Comparison to Uncoated TKA

Status
Active, not recruiting
Phases
NA
Study type
Interventional
Source
ClinicalTrials.gov
Registry ID
NCT03424174
Acronym
TKA
Enrollment
80
Registered
2018-02-06
Start date
2017-01-04
Completion date
2028-12-31
Last updated
2024-08-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Keywords

TKA, cytokine, coating

Brief summary

Comparison of coated and uncoated TKA with regard to cytokine expression and clinical results

Detailed description

Comparison of coated and uncoated TKA with regard to cytokine expression and clinical results at 3 months, 1 year and 3 years after surgery

Interventions

Implantation coated Total Knee Arthroplasty

Implantation StandardTotal Knee Arthroplasty

Sponsors

Technische Universität Dresden
Lead SponsorOTHER

Study design

Allocation
RANDOMIZED
Intervention model
PARALLEL
Primary purpose
TREATMENT
Masking
NONE

Eligibility

Sex/Gender
ALL
Age
18 Years to No maximum
Healthy volunteers
No

Inclusion criteria

* Primary and secondary osteoarthritis * understanding of german language

Exclusion criteria

* necessity of constrained TKA * existence of other joint implants

Design outcomes

Primary

MeasureTime frameDescription
cytokine expressionpre-op, 1 and 3 years post-opChanges of cytokine expression 1 and 3 years after surgery compared to pre-op

Secondary

MeasureTime frameDescription
Function assessed with Knee Society Scorepre-op, 3 months, 1 and 3 years post-opKnee Society Score (0 - 100 points, best 100)
Patient reported outcome assessed with Oxford Knee Scorepre-op, 3 months, 1 and 3 years post-opOxford Knee Score (0 - 48 points, best 48)
Quality of life assessed with EQ 5Dpre-op, 3 months, 1 and 3 years post-opEQ 5D Index (0 - 1.0, best 1.0)
Activity assessed with UCLA activity scorepre-op, 3 months, 1 and 3 years post-opUCLA activity score (0 - 10 points, best 10)

Other

MeasureTime frameDescription
adverse events3 month, 1 year and 3 years post-opadverse events

Countries

Germany

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 7, 2026